PureTech Health plc
PureTech Health plc - ADR is a biotechnology company that innovates by discovering and developing new therapies designed to address significant medical challenges. As an American Depositary Receipt (ADR), it allows US investors to gain exposure to PureTech’s shares, which are primarily traded on the London Stock Exchange. This structure facilitates the engagement of US market participants by converting the shares into a form traded domestically. The company's core focus lies in the development of advanced medicine in fields like immunology, oncology, and neuroscience, offering solutions that target biological and clinical pathways that have not been previously utilized in modern treatments. By integrating cutting-edge science with commercialization expertise, PureTech is poised to make an impact in the healthcare industry. The ADR format makes the company’s innovative efforts accessible to a broader investor base, enhancing its reach and influence in the biotechnology sector. PureTech Health plc is dedicated to advancing healthcare solutions and is a significant player in shaping the future of medicine.
$14.56
-$0.34 (-2.28%)
Price from 2 days ago
The business is unprofitable at the operating level (-2114.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 8.0%, steady but not accelerating.
Negative free cash flow of -$85M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$5M
▲ +8.0% YoY
Net Income (TTM)
-$110M
▼ -496.2% YoY
Op. Margin
-2114.72%
▲ +1039.3pp YoY
ROIC
-20.60%
▲ +9.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$85M
▲ +36.6% YoY
Op. Cash Flow (TTM)
-$85M
▲ +36.6% YoY
Net Debt
-$258M
Net Cash Position
Cash & Equiv.
$277M
3Y CAGR: +30.6%
Continue Research
Is PureTech Health (PRTC) overvalued?
PureTech Health (PRTC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, PureTech Health scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is PureTech Health a high-quality business?+
PureTech Health scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -2,114.7% operating margin and a -20.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is PureTech Health a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh PRTC's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.